Bedrijfsoverzicht
Sonoma Pharmaceuticals, Inc. is a specialized developer and producer focused on stabilized hypochlorous acid (HOCl) products designed for a diverse range of therapeutic applications. These products target wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions across global markets including the United States, Europe, Asia, Latin America, and international regions. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, which distinguishes it from broad pharmaceutical giants by focusing on niche therapeutic areas and generic formulations. Sonoma currently maintains a market capitalization of $3.95M and generates annual revenue of $17.72M while employing a workforce of 8 individuals. The combination of a market cap under $40 million and a revenue stream of approximately $17.7 million indicates that the company operates on a small-cap scale, suggesting it is an early-stage or specialized entity rather than a large-scale commercial pharmaceutical enterprise.
Financiële gezondheid
The company reported revenue of $17.72M for the trailing twelve months (TTM), while net income stood at -$3,370,000 and EBITDA was -$2,629,000. The substantial gap between the positive revenue of $17.72M and the negative net income of -$3,370,000 reveals a cost structure where expenses significantly exceed gross profits, resulting in a loss on a per-dollar-of-sales basis. Free cash flow is reported at -$3,573,750, which indicates that the company is currently burning cash and lacks the internal liquidity to fund operations without external capital injections or financing activities. The gross margin stands at 38.2%, which suggests that the cost of goods sold consumes 61.8% of revenue before other operating expenses are deducted. However, the operating margin is negative at -15.6%, and the profit margin is further compressed to -19.0%, indicating that significant administrative, research, or sales expenses are eroding the gross profitability. On the balance sheet, the company holds $2.56M in cash against total debt of $655,000, creating a liquidity buffer despite the negative cash flow from operations. The debt-to-equity ratio is calculated at 19.09, which, when viewed alongside the high cash position, presents a mixed picture of leverage that must be interpreted carefully in the context of a private or thinly traded small-cap firm. The current ratio is 2.88, which indicates a strong short-term liquidity position where current assets are nearly three times current liabilities. Return on Equity is -81.2% and Return on Assets is -12.7%, metrics that reveal that management has not yet generated positive returns on the capital invested or the assets owned, reflecting the company's current stage of development or the high costs associated with its specialized product line.
Waarderingsbeoordeling
The trailing P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is -4.07. The existence of a negative forward P/E implies that analysts or market data providers are projecting continued losses or have adjusted earnings expectations based on the current financial trajectory. The price-to-book ratio is 1.15, which indicates that the market values the company's equity at a slight premium over its book value, suggesting some level of intangible asset value or future growth potential that is priced in. The price-to-sales ratio is 0.22, a low multiple that suggests the market is valuing the company based on a fraction of its revenue, often seen in biotech or specialty drug firms awaiting clinical success or revenue expansion. The EV/EBITDA stands at -0.78, a negative multiple that reinforces the company's inability to generate earnings before interest, taxes, depreciation, and amortization at this point in time. Regarding price metrics, the stock has a 52-week high of $6.92 and a 52-week low of $2.00. Without a specific current price provided in the facts, the valuation context is strictly defined by this historical range where the stock has demonstrated significant volatility, trading within a band of nearly 500% in value over the past year. The beta is 1.76, which means the stock's price volatility is substantially higher than the broader market, moving with roughly 1.76 times the intensity of the market index.
Growth & Income
Revenue growth for the year-over-year period is 22.0%, demonstrating a robust expansion in sales volume or pricing for the HOCl product portfolio. Earnings growth is listed as N/A because the company is currently unprofitable with a net income of -$3,370,000, meaning earnings cannot be compared to revenue growth in a traditional sense of expanding profitability. As the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company reinvests its limited resources, such as the $2.56M in cash, into research, development, and operational scaling to achieve future profitability. The overall growth and income profile is characterized by strong top-line revenue expansion of 22.0% paired with a complete absence of dividend income and current profitability, typical for specialty pharmaceutical companies in the development or early commercialization phase.